Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from Darthmouth-Hitchcock Medical Center describe new findings in cancer vaccines
February 27th, 2007
A report, "Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang," is newly published data in Clinical Cancer Research. "In patients with progressive malignancy, the natural balance between proinflammatory (Yang) and inhibitory (regulatory or Yin) immune pathways is disrupted and favors cancer-specific immune suppression. Therapy with interleukin 2 (IL-2) can mobilize immune effector cells that recognize and destroy cancer," investigators in Lebanon report. "High-dose IL-2 is the only therapy that has consistently induced complete durable remissions in patients with metastatic renal cell carcinoma (RCC) but only in a few of them. The...
Source: Cancer Weekly (2007-02-27)
|
